APOB and obesity due to melanocortin 4 receptor deficiency: These insights are now reflected in contemporary clinical guidelines, which increasingly recognize non-HDL-C and Apo B as secondary or alternative targets for lipid management, particularly in patients with diabetes, obesity, or mixed dyslipidemia [6,7].